No profile data available.
Sionna Therapeutics, Inc. (SION) is a healthcare company in the lung treatment pharmaceuticals industry, based in Waltham, United States, with about 59 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$75.27 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $221.54 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
Sionna Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$221.54 million as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Gyre Therapeutics, Inc. (GYRE), 4D Molecular Therapeutics, Inc. (FDMT), Upstream Bio, Inc. (UPB), Rein Therapeutics Inc. (RNTX).